Paradigm Therapeutics

Executive Summary

Paradigm Therapeutics is a private US-based biopharmaceutical company dedicated to developing innovative therapies for serious rare diseases. Its lead candidate, Zorblesia (SD-101), is a proprietary topical therapy for Epidermolysis Bullosa (EB), a devastating genetic disorder with no approved treatments. The company focuses on high unmet medical needs in underserved patient populations. Paradigm's early-stage pipeline and targeted approach position it as a potential player in the rare disease space, though clinical and regulatory risks remain high.

Upcoming Catalysts (preview)

• TBDPhase 2 clinical trial results for Zorblesia (SD-101) in Epidermolysis Bullosa40% success
• TBDRegulatory guidance meeting with FDA on development pathway70% success
• TBDPotential partnership or licensing deal for SD-101 or pipeline50% success